Paclitaxel

目录号:S1150 别名: NSC 125973

Paclitaxel Chemical Structure

Molecular Weight(MW): 853.91

Paclitaxel是一种microtubule聚合物稳定剂,在人内皮细胞中IC50为0.1 pM。

规格 价格 库存 购买数量  
RMB 749.07 现货
RMB 571.49 现货
RMB 2235.46 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献22篇:

客户使用该产品的6个实验数据:

  • (F) Kaplan-Meier curves are shown for all groups described: no hydrogel, a hydrogel loaded with paclitaxel, or a hydrogel loaded with doxorubicin. The number of mice per group (n) and median survival (ms) are listed. The experiment was performed at least three times.

    Science, 2018, 10(433), doi: 10.1126/scitranslmed.aar1916. Paclitaxel purchased from Selleck.

    Effect of tivantinib on the mitotic index was compared with the antimitotic drugs paclitaxel and vinblastine after overnight treatment of the HLE cell line with two different concentrations of each drug.

    Clin Cancer Res, 2017, 23(15):4364-4375. Paclitaxel purchased from Selleck.

  • Characterization of nuclear damage by PARP as DNA damage repair marker. CLSM images of dual drug conjugated nanoparticle treatments to HeLa cells for 24 h at their respective IC50 drug dosages compared to nontreated control. Cells were stained with PARP-Alexafluor 488 antibody (green).

    ACS Appl Mater Interfaces, 2015, 7(14): 7584-98. Paclitaxel purchased from Selleck.

    Inhibitory effect of lenvatinib and paclitaxel on the proliferation of ATC cells. Cells were treated with the indicated concentrations of lenvatinib (A) and paclitaxel (B) for 48 h, followed by MTT assay to evaluate cell proliferation. IC50 values of these two drugs for each cell line were calculated using the Reed-Muench method

    Am J Cancer Res, 2017, 7(4):903-912. Paclitaxel purchased from Selleck.

  • Western blot analysis of pPRAS40 (T246), pS6 (S240/S244), and pS6 (S235/S236) proteins in (A) HeyA8 cells and (B) SKOV3 cells treated with 0.37 μM or 10 μM paclitaxel in three-dimensional cell culture for 24 hours.

    PLoS One, 2016, 11(5):e0155052. . Paclitaxel purchased from Selleck.

    Microscope image (406) magnification of U937 cells after exposure to SM-TNs. a) Untreated U937 cells. b) U937 cells treated with 200 nM, and 35 nM ODS empty shells. c) U937 cells treated with microcrystalline (free) Taxol prepared by sonicating Taxol in 20%H3PO4/0.8% SDS solution. d) U937 cells treated with 200 nM SM-TN. A SM-TN is seen in the middle of the picture. e) U937 cells treated with 35 nM SMTN.The nanowires are too small to see at this magnification, but their effect on the cells is clearly visible. Scale bar = 10 mm.

    RSC Adv 2011 1, 884-892. Paclitaxel purchased from Selleck.

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述 Paclitaxel是一种microtubule聚合物稳定剂,在人内皮细胞中IC50为0.1 pM。
特性 Paclitaxel 是有丝分裂抑制剂。
靶点
Microtubule (human endothelial cells) [1]
0.1 pM
体外研究

Paclitaxel在104到 105倍更高浓度时,抑制非内皮性人类细胞,IC50 为1 nM -10 nM。Paclitaxel选择性抑制细胞增殖,具有种属特异性,在Paclitaxel极低浓度时,小鼠内皮细胞对 Paclitaxel不敏感。 极低浓度Paclitaxel抑制 人类内皮细胞,但是不影响细胞微管结构,且处理的细胞在 G2/M 期没有出现细胞周期停滞和凋亡,说明这是一种新型尚未查明的作用机制。在体外血管生成实验中,在三维纤维蛋白基质中,极低浓度Paclitaxel阻断人类内皮细胞形成芽管。[1] 在SMF存在时, Paclitaxel 作用于 K562 细胞的有效浓度从50 ng/ml降低到 10 ng/ml。在有或无SMF时,Paclitaxel 使K562 细胞周期停滞与DNA损伤相关。[2] Paclitaxel单独处理四种细胞系,包括A549 细胞,H358, H1395 细胞和H1666 细胞,抑制CDK1,这种作用存在时间依赖性。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
TE-15 M17Nd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHqeXFwUUN3ME2wMlAxODJ6NzFOwG0> MYXTRW5ITVJ?
LC-2-ad NIrR[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTBwMECwN|E4KM7:TR?= M3TBZ3NCVkeHUh?=
RL95-2 NIniZVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVq3NXNVUUN3ME2wMlAxODZ4ODFOwG0> NIjWN4tUSU6JRWK=
MZ1-PC NY\uR292T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfKTWM2OD1yLkCwNFczQSEQvF2= M4X2ZXNCVkeHUh?=
TE-8 NUjVT4NnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFf1d4ZKSzVyPUCuNFAyOTdizszN MV3TRW5ITVJ?
SW954 M{HyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LGSWlEPTB;MD6wNFEyQSEQvF2= MUnTRW5ITVJ?
TE-11 NWq3cnllT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrEdlJKSzVyPUCuNFAyOjNizszN MU\TRW5ITVJ?
PSN1 NWLMU4ZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvsOmtJUUN3ME2wMlAxOTNizszN MVfTRW5ITVJ?
MOLT-4 NXruTWRsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHjPcYxKSzVyPUCuNFAyPDlizszN MVLTRW5ITVJ?
697 NUXzV5F{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnGeFJ[UUN3ME2wMlAxOTVizszN NEDoUJpUSU6JRWK=
ETK-1 NWqwfmlpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLrXotkUUN3ME2wMlAxOTV{IN88US=> NFPBNWRUSU6JRWK=
TE-10 NGXKWVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnGWJVKSzVyPUCuNFAyPTRizszN MmfEV2FPT0WU
HUTU-80 M3z3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC1XVJKSzVyPUCuNFAyPjhizszN MVvTRW5ITVJ?
NTERA-S-cl-D1 NXnxSnpHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPsTWM2OD1yLkCwNlA6KM7:TR?= M2ntenNCVkeHUh?=
MFH-ino MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLvTWM2OD1yLkCwNlY5KM7:TR?= MWfTRW5ITVJ?
IA-LM NV3We25MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7tdI5KSzVyPUCuNFAzQCEQvF2= NIrifJpUSU6JRWK=
MC116 M13n[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjSdnNDUUN3ME2wMlAxOjh7IN88US=> MWnTRW5ITVJ?
RKO NEPPNoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fYXWlEPTB;MD6wNFI6QCEQvF2= NYLwWmhwW0GQR1XS
MRK-nu-1 NViwTJY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PNe2lEPTB;MD6wNFI6QSEQvF2= MVPTRW5ITVJ?
VA-ES-BJ MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXOzZ5M3UUN3ME2wMlAxOyEQvF2= Mm\DV2FPT0WU
KALS-1 NFzscopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLKTWM2OD1yLkCwN|A5KM7:TR?= MUXTRW5ITVJ?
BB30-HNC Moi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXHV5NKSzVyPUCuNFA{OTRizszN M{f6SXNCVkeHUh?=
ACN MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1H6Z2lEPTB;MD6wNFMyPiEQvF2= Mlu5V2FPT0WU
TE-9 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTBwMECzNlYh|ryP MXfTRW5ITVJ?
SIG-M5 NU\qV|h1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXqzc2hQUUN3ME2wMlAxOzJ5IN88US=> NGTONY9USU6JRWK=
no-10 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrwVIdKSzVyPUCuNFA{PjJizszN M2\RdHNCVkeHUh?=
EW-1 NGCxWmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr3VnlKSzVyPUCuNFA{PzFizszN Mnv4V2FPT0WU
SK-LMS-1 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfRTWM2OD1yLkCwOFAyKM7:TR?= NE[1eVRUSU6JRWK=
GT3TKB M4\IfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;YeY5lUUN3ME2wMlAxPDN2IN88US=> MnyyV2FPT0WU
ES4 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV34dJk1UUN3ME2wMlAxPDR7IN88US=> NYTOcHBPW0GQR1XS
IMR-5 Ml;XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTBwMEC0OUDPxE1? MnXEV2FPT0WU
NCI-H1648 NYT6[lFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEC0Olkh|ryP MnflV2FPT0WU
MV-4-11 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml2yTWM2OD1yLkCwOFc2KM7:TR?= M3fBdHNCVkeHUh?=
SK-UT-1 MmjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfWTWM2OD1yLkCwOFgh|ryP NVfGVo9{W0GQR1XS
NB13 NWjFc|FET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XqUmlEPTB;MD6wNFQ6OSEQvF2= M1;nSnNCVkeHUh?=
DJM-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXHOboRpUUN3ME2wMlAxPTNizszN MoPzV2FPT0WU
ES8 NWX3ZWU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{fSN2lEPTB;MD6wNFU{QCEQvF2= M2jUXnNCVkeHUh?=
TE-6 M3nP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLOeGFYUUN3ME2wMlAxPTdizszN NVzid45nW0GQR1XS
KS-1 NVe4ZnlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnuyTWM2OD1yLkCwOVgzKM7:TR?= MnzIV2FPT0WU
TE-1 NV7YZnNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\Bd|Y1UUN3ME2wMlAxPjB4IN88US=> NET0UGJUSU6JRWK=
ATN-1 NH7YTXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonxTWM2OD1yLkCwOlA6KM7:TR?= NG[yVHBUSU6JRWK=
A4-Fuk NHX6PWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDBZZRtUUN3ME2wMlAxPjFzIN88US=> NFvGcJZUSU6JRWK=
ALL-PO MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1z1[GlEPTB;MD6wNFY{KM7:TR?= MkPIV2FPT0WU
BE-13 M3\EXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTBwMEC2N|Yh|ryP M3THXnNCVkeHUh?=
KM12 NYPsUGt3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTZUWp6UUN3ME2wMlAxPjN5IN88US=> MoK0V2FPT0WU
NOS-1 NGDyU3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwMEC2OUDPxE1? M3jnW3NCVkeHUh?=
SW962 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVrJR|UxRTBwMEC2OlIh|ryP NHHVRo1USU6JRWK=
OCUB-M M{DCe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHPTVVKSzVyPUCuNFA3PjJizszN NHvGUG5USU6JRWK=
NCI-H510A NYLBNXBWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEC2OlUh|ryP M1S0TXNCVkeHUh?=
EW-16 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTBwMEC2PVQh|ryP NVPwO5NlW0GQR1XS
KGN MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r1OWlEPTB;MD6wNFcyOiEQvF2= MUPTRW5ITVJ?
LS-411N NFrhOWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjoTWM2OD1yLkCwO|E4KM7:TR?= M1;B[HNCVkeHUh?=
Becker MlLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTBwMEC3NkDPxE1? Ml24V2FPT0WU
HC-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DKR2lEPTB;MD6wNFczOSEQvF2= MYfTRW5ITVJ?
CESS NHfXN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zTPGlEPTB;MD6wNFc{PyEQvF2= M1PBbHNCVkeHUh?=
KURAMOCHI NHTqbFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PufWlEPTB;MD6wNFc1QCEQvF2= M1;JZnNCVkeHUh?=
TGBC24TKB NF7Dbo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTBwMEC3OVIh|ryP M1zVRXNCVkeHUh?=
SW982 NWS5fGg6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTBwMEC3OlYh|ryP MWPTRW5ITVJ?
HCE-4 MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TVNWlEPTB;MD6wNFc3PyEQvF2= M2LNbXNCVkeHUh?=
LOUCY M2PwNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfMbItIUUN3ME2wMlAxPzd3IN88US=> NGrs[mZUSU6JRWK=
8-MG-BA MoLXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDSTWM2OD1yLkCwO|k3KM7:TR?= MWPTRW5ITVJ?
HT-144 NECzXZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwMEC4JO69VQ>? NY\hWFEzW0GQR1XS
LXF-289 M4rmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwMEC4NVgh|ryP NIj1WphUSU6JRWK=
RS4-11 NEn6Um1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTBwMEC4N|Yh|ryP NHTpfZRUSU6JRWK=
DEL M3njfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoWyTWM2OD1yLkCwPFQ2KM7:TR?= M1;TSXNCVkeHUh?=
OCI-AML2 NGDvbmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYL0T3loUUN3ME2wMlAxQDV{IN88US=> MmTQV2FPT0WU
CCRF-CEM NWjR[oFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jtbWlEPTB;MD6wNFg4OSEQvF2= MXXTRW5ITVJ?
A388 M3OwOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvrOZhjUUN3ME2wMlAxQDd2IN88US=> MYPTRW5ITVJ?
KNS-42 NFjpSVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTwTIFKSzVyPUCuNFA5QTFizszN M2TmeXNCVkeHUh?=
OVCAR-4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEC5NFQh|ryP NUHvSG5iW0GQR1XS
NCI-H1355 M{jOUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUn0OWlZUUN3ME2wMlAxQTF2IN88US=> M3HpWnNCVkeHUh?=
BL-70 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fGPGlEPTB;MD6wNFk{KM7:TR?= NFX3U3FUSU6JRWK=
BL-41 M{HZSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHjXGRrUUN3ME2wMlAxQTN2IN88US=> NIrvZ|NUSU6JRWK=
A101D M4fYcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTBwMEC5OkDPxE1? MV;TRW5ITVJ?
HL-60 MoLTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwMEC5OlYh|ryP M4j3bnNCVkeHUh?=
COR-L279 NVrwV5pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEC5PVkh|ryP NUXJfpJsW0GQR1XS
NCI-SNU-16 MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEGwNFgh|ryP MXfTRW5ITVJ?
Calu-6 NGjHe|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMEGwNVIh|ryP M3XJS3NCVkeHUh?=
SR NUXaRWRuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2P3cGlEPTB;MD6wNVAzPiEQvF2= M1PUNXNCVkeHUh?=
QIMR-WIL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvhUHdKSzVyPUCuNFExOzNizszN NX\FeWRqW0GQR1XS
LB647-SCLC NE\BU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;WNGlEPTB;MD6wNVA2OSEQvF2= NGnJZm1USU6JRWK=
RPMI-8226 NWO4TWpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTBwMEGxNFIh|ryP NXTXOWtoW0GQR1XS
SK-PN-DW MnHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnDTWM2OD1yLkCxNVEzKM7:TR?= MkfKV2FPT0WU
SF268 NIfYOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXG2[m9DUUN3ME2wMlAyOTVzIN88US=> NVPoeIFFW0GQR1XS
HD-MY-Z NIn3WWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;XTWM2OD1yLkCxNVY{KM7:TR?= NH7NcIpUSU6JRWK=
DOHH-2 M1u0VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDUTWM2OD1yLkCxNlA{KM7:TR?= MknEV2FPT0WU
SCC-3 M3ixcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjDZmExUUN3ME2wMlAyOjB2IN88US=> MmXWV2FPT0WU
ST486 NVv4SYpJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NG\pemxKSzVyPUCuNFEzODRizszN MVrTRW5ITVJ?
NALM-6 M4Lqfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHe2bW5KSzVyPUCuNFEzOTRizszN MV7TRW5ITVJ?
NCI-H1436 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnmbpZqUUN3ME2wMlAyOjNzIN88US=> NWr3NXBqW0GQR1XS
KE-37 MnLJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH2wc41KSzVyPUCuNFEzOzRizszN MXfTRW5ITVJ?
RPMI-8402 Ml3WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTBwMEGyOVYh|ryP M3ToSHNCVkeHUh?=
RXF393 NXnjblBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPzTWM2OD1yLkCxNlU4KM7:TR?= M4fyUHNCVkeHUh?=
KARPAS-45 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMEGyO{DPxE1? Ml;sV2FPT0WU
HOP-62 M3jmZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLaTWM2OD1yLkCxNlc3KM7:TR?= NWfLUY1MW0GQR1XS
ES1 M{Lk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPlfJhKSzVyPUCuNFEzQDhizszN M{LQOHNCVkeHUh?=
L-363 NXXJc5ZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TKN2lEPTB;MD6wNVM2OSEQvF2= NHfxd3dUSU6JRWK=
GI-1 NIi1XFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTBwMEGzO|Mh|ryP NXrNN4tqW0GQR1XS
CTV-1 NI\jVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEG0O|gh|ryP NGjMT2dUSU6JRWK=
TE-5 NHnTcYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjCNIEyUUN3ME2wMlAyPDl4IN88US=> MVzTRW5ITVJ?
SNU-C2B MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17ucGlEPTB;MD6wNVQ6PiEQvF2= NFzNc5BUSU6JRWK=
K-562 M1HjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwMEG1NVYh|ryP MWnTRW5ITVJ?
SNB75 NGLHeY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1;PXGlEPTB;MD6wNVU1KM7:TR?= M1LC[nNCVkeHUh?=
MOLT-13 M{nJN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWr5NlBOUUN3ME2wMlAyPjN5IN88US=> NETVOldUSU6JRWK=
LS-123 NF;ifXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfDTWM2OD1yLkCxOlY1KM7:TR?= MkDxV2FPT0WU
NCI-SNU-5 Mn;SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGO2PFdKSzVyPUCuNFE4ODFizszN MlLYV2FPT0WU
Daudi NIHO[JFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vKbmlEPTB;MD6wNVcxQCEQvF2= M4LBUXNCVkeHUh?=
A253 NILFT21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTBwMEG3N|gh|ryP NHTIRXBUSU6JRWK=
TGBC1TKB NIjN[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGr2dJVKSzVyPUCuNFE4PTJizszN MYfTRW5ITVJ?
SJSA-1 NH3kXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTiTWM2OD1yLkCxO|Y4KM7:TR?= M1XpSnNCVkeHUh?=
NCCIT MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3WzUmlEPTB;MD6wNVc3QSEQvF2= NFvnXVlUSU6JRWK=
NCI-H69 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXpOVZKSzVyPUCuNFE4PzhizszN NXLjU|V[W0GQR1XS
SH-4 MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTBwMEG4PVUh|ryP NG\EZmtUSU6JRWK=
HCC1187 MlLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXkTWM2OD1yLkCxPVI1KM7:TR?= M1rsXnNCVkeHUh?=
HCC1599 NVf5foNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q0UmlEPTB;MD6wNlAzKM7:TR?= NVfZPWdDW0GQR1XS
ONS-76 MnT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID2Xo5KSzVyPUCuNFIxOzZizszN NYTaeohKW0GQR1XS
KU812 MlT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHHTWM2OD1yLkCyNFM6KM7:TR?= NH7EPXBUSU6JRWK=
ML-2 NVXid3puT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUnYN|VCUUN3ME2wMlAzODR5IN88US=> NVXBXo5HW0GQR1XS
HCE-T MlXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{P0WWlEPTB;MD6wNlA6OiEQvF2= MlnWV2FPT0WU
NCI-H446 NYLrbVY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTBwMEKxNVIh|ryP NHvZZ|lUSU6JRWK=
RPMI-6666 MonpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTBwMEKxOFkh|ryP M1nCfXNCVkeHUh?=
MOLT-16 MoKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlmxTWM2OD1yLkCyNVU{KM7:TR?= MUDTRW5ITVJ?
JiyoyeP-2003 NHS5bVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwMEKxO|Yh|ryP NHfue|FUSU6JRWK=
MHH-PREB-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnhd5pxUUN3ME2wMlAzOTlzIN88US=> M2nwfHNCVkeHUh?=
MC-CAR M{[1Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL3XXR[UUN3ME2wMlAzOzJ4IN88US=> NWroboF1W0GQR1XS
BC-3 NVjJcI5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTjdlhbUUN3ME2wMlAzOzR2IN88US=> NHS2NZdUSU6JRWK=
KINGS-1 NUntVYZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TEfGlEPTB;MD6wNlM2PSEQvF2= M176SnNCVkeHUh?=
PF-382 Mn7aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjvV|dKSzVyPUCuNFI{PzhizszN M2iwR3NCVkeHUh?=
J-RT3-T3-5 M3;XWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmP4TWM2OD1yLkCyN|g{KM7:TR?= M2HjRnNCVkeHUh?=
SF539 NEjPOWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLM[JZOUUN3ME2wMlAzPDBzIN88US=> NUP6WVRYW0GQR1XS
LB831-BLC M2XGWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mke3TWM2OD1yLkCyOFg2KM7:TR?= NFS1TFhUSU6JRWK=
DMS-114 NGPKcmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTBwMEK1NFIh|ryP NYDqWZh3W0GQR1XS
LB1047-RCC NWi3d3c5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XhZmlEPTB;MD6wNlUyKM7:TR?= NXXmNGNpW0GQR1XS
LB771-HNC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrrTWM2OD1yLkCyOVM1KM7:TR?= NXzUZldZW0GQR1XS
BB65-RCC NHntRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXWTWM2OD1yLkCyOVM1KM7:TR?= NV3GN|B3W0GQR1XS
BV-173 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zjemlEPTB;MD6wNlU2PCEQvF2= M2nmNHNCVkeHUh?=
ARH-77 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\UeZFZUUN3ME2wMlAzPjBzIN88US=> NULVZYVwW0GQR1XS
IST-MEL1 NH[2SI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHoUVNOUUN3ME2wMlAzPjJ|IN88US=> NFfyUXhUSU6JRWK=
NB1 NYXuOWZET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTiRoxKSzVyPUCuNFI3QDdizszN MlrFV2FPT0WU
EoL-1-cell M2rzOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XaOmlEPTB;MD6wNlY5QCEQvF2= MYrTRW5ITVJ?
KY821 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwMEK2PVch|ryP M2Hhb3NCVkeHUh?=
CMK Ml;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjTb3FOUUN3ME2wMlAzPzN2IN88US=> M1LPR3NCVkeHUh?=
NCI-H2126 NVjZdpBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwMEK3Olgh|ryP MV\TRW5ITVJ?
NCI-H526 MoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIGweJZKSzVyPUCuNFI5QTFizszN NHrIc2tUSU6JRWK=
COLO-684 NFnLem9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonhTWM2OD1yLkCyPVA5KM7:TR?= M2rZW3NCVkeHUh?=
NCI-H747 M1PBWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTheog6UUN3ME2wMlAzQTN|IN88US=> NF\vOoVUSU6JRWK=
JAR NFrpcXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mni5TWM2OD1yLkCyPVQ3KM7:TR?= Mnu5V2FPT0WU
MEG-01 NV[0UWR4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYTJR|UxRTBwMEK5O|gh|ryP MX;TRW5ITVJ?
MONO-MAC-6 NIO3dYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz3TWM2OD1yLkCzNFI{KM7:TR?= NHjET2hUSU6JRWK=
IST-SL1 M4e5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTBwMEOwOFIh|ryP NEjSUGZUSU6JRWK=
CPC-N MmfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3STo1KSzVyPUCuNFMxPzlizszN MoPTV2FPT0WU
NCI-H1963 M4fQcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMEOxN|Eh|ryP MkDEV2FPT0WU
K052 MlXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi2e|h3UUN3ME2wMlA{OjR5IN88US=> NX3pNY5DW0GQR1XS
KM-H2 M1vldGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXzJR|UxRTBwMEOzNFch|ryP NYHweWh5W0GQR1XS
TE-12 NWfJOlJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXLJR|UxRTBwMEOzNFkh|ryP NVzicmd1W0GQR1XS
TK10 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIKxT4ZKSzVyPUCuNFM{PTZizszN M362NXNCVkeHUh?=
NMC-G1 M{Lt[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTQTWM2OD1yLkCzOFUzKM7:TR?= M2PoenNCVkeHUh?=
no-11 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;QZmx4UUN3ME2wMlA{PDd6IN88US=> MVPTRW5ITVJ?
NCI-H524 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\zbJJUUUN3ME2wMlA{PTJ7IN88US=> MlviV2FPT0WU
MHH-CALL-2 MnHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTPZZRKSzVyPUCuNFM2PjJizszN NUX2[ItRW0GQR1XS
GB-1 NEn0TWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrNNnVZUUN3ME2wMlA{PiEQvF2= MoTFV2FPT0WU
OPM-2 MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTBwMEO2O|Mh|ryP M{TlZXNCVkeHUh?=
RH-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEO4NVkh|ryP MXfTRW5ITVJ?
NCI-H64 NGmwc|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmj6TWM2OD1yLkCzPFU4KM7:TR?= NGfCdmNUSU6JRWK=
EVSA-T NXrkVFZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nRTmlEPTB;MD6wN|kzOyEQvF2= MYLTRW5ITVJ?
KARPAS-299 MmPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2X0W2lEPTB;MD6wN|k5KM7:TR?= NXK0W5piW0GQR1XS
MZ7-mel NFKwVINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXH5U5JUUUN3ME2wMlA1ODRizszN M2L4[HNCVkeHUh?=
LB373-MEL-D MnPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofWTWM2OD1yLkC0NVA2KM7:TR?= MUnTRW5ITVJ?
HEL MnzaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmm3TWM2OD1yLkC0NVQh|ryP NGn5coFUSU6JRWK=
SW872 NV7CbmRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljGTWM2OD1yLkC0NlEh|ryP MYjTRW5ITVJ?
DU-4475 NIT4Z3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfM[llZUUN3ME2wMlA1OjR2IN88US=> M4\J[HNCVkeHUh?=
IST-SL2 NH\t[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jRXGlEPTB;MD6wOFI4PSEQvF2= M17od3NCVkeHUh?=
NCI-H82 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY[4[mI3UUN3ME2wMlA1OzB5IN88US=> NG\tS5BUSU6JRWK=
LC4-1 NEXkRXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTBwMESzOVEh|ryP MnvjV2FPT0WU
HDLM-2 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHe3ZXpKSzVyPUCuNFQ{QTJizszN M3j0O3NCVkeHUh?=
MMAC-SF MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYD5PFRUUUN3ME2wMlA1PTN2IN88US=> Mo\kV2FPT0WU
L-540 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1e1XGlEPTB;MD6wOFY{QSEQvF2= M{jybHNCVkeHUh?=
MZ2-MEL M4W3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS3XpVKSzVyPUCuNFQ4PDJizszN NFHOT4tUSU6JRWK=
LU-134-A NHn5[3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T3[WlEPTB;MD6wOFc4OyEQvF2= NIPBNoVUSU6JRWK=
UACC-257 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTFTWM2OD1yLkC0PFQ6KM7:TR?= NV:2e5I4W0GQR1XS
NCI-H1581 M1rWU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTBwMES5OVMh|ryP NYLFcGJRW0GQR1XS
NB17 NF:1eWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTBwMES5O|kh|ryP NIT6dZFUSU6JRWK=
SBC-1 NHflSJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPuTWM2OD1yLkC1NFQzKM7:TR?= NWfhTotVW0GQR1XS
TALL-1 M2PkSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7ITWM2OD1yLkC1NFQ2KM7:TR?= NUTMbnBFW0GQR1XS
NCI-H1304 NHriVXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXe1cVVkUUN3ME2wMlA2OjB6IN88US=> Ml\5V2FPT0WU
NEC8 NYXJdVF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTBwMEWyPFYh|ryP M2XDcnNCVkeHUh?=
CAL-148 NYLXemF7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorsTWM2OD1yLkC1OFM6KM7:TR?= MWHTRW5ITVJ?
CGTH-W-1 NHHM[ldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PEd2lEPTB;MD6wOVQ1QSEQvF2= NXrseWp2W0GQR1XS
NCI-H889 MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXITWM2OD1yLkC1OVkzKM7:TR?= NGXyOopUSU6JRWK=
GR-ST MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrlboNKSzVyPUCuNFU3OjFizszN NH\3VIJUSU6JRWK=
KARPAS-422 M4W5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1j1emlEPTB;MD6wOVY2KM7:TR?= MUfTRW5ITVJ?
RPMI-8866 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XpRmlEPTB;MD6wOVcyOiEQvF2= M2jWOHNCVkeHUh?=
SCLC-21H MoraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTHTWM2OD1yLkC1PFg1KM7:TR?= NIjp[5ZUSU6JRWK=
COR-L88 NUnHVWV2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTBwMEW5Nlch|ryP NWDPe4NwW0GQR1XS
LU-139 NHPGR2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHyTWM2OD1yLkC1PVg3KM7:TR?= NXHFbJFNW0GQR1XS
SF126 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYOyUGJFUUN3ME2wMlA3OTN|IN88US=> MoXEV2FPT0WU
NCI-H1882 MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTBwME[0NlQh|ryP NHzHb3lUSU6JRWK=
EW-24 M1zyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7sOlJuUUN3ME2wMlA3PDh|IN88US=> MWrTRW5ITVJ?
CP67-MEL M4[4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1K5dWlEPTB;MD6wOlgyKM7:TR?= NUS0bVBGW0GQR1XS
DG-75 NEf6N5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfLTWM2OD1yLkC2PFk6KM7:TR?= M{nLc3NCVkeHUh?=
LOXIMVI NEjoTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn64TWM2OD1yLkC3NFI5KM7:TR?= MWrTRW5ITVJ?
HH NEPneXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV2zTJlGUUN3ME2wMlA4OTV5IN88US=> MYnTRW5ITVJ?
K5 M1\jV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fWcGlEPTB;MD6wO|IzPiEQvF2= NXTDboFKW0GQR1XS
EC-GI-10 M2rtZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHWyWm9KSzVyPUCuNFczPTdizszN MVjTRW5ITVJ?
SK-N-DZ MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\RfmlEPTB;MD6wO|MxPyEQvF2= MnmzV2FPT0WU
A3-KAW M2PxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\QZ5NoUUN3ME2wMlA4OzVzIN88US=> M1ntS3NCVkeHUh?=
MLMA NYj6cohLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXDTWM2OD1yLkC3OFY2KM7:TR?= NWnwSHBbW0GQR1XS
LB996-RCC NUHxcpN2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\2Z4VKSzVyPUCuNFc4ODdizszN NFLnVlVUSU6JRWK=
OS-RC-2 NX;lXJNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTBwMEe3OFgh|ryP MkfwV2FPT0WU
CTB-1 NHjmfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLGS5hIUUN3ME2wMlA4QDFizszN NUfueHoxW0GQR1XS
IST-MES1 MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\BU2lEPTB;MD6wO|kyOiEQvF2= NGfOUJFUSU6JRWK=
LS-1034 NXf5c3BkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDCboVKSzVyPUCuNFgxOzVizszN NFS0NZRUSU6JRWK=
HT MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnG4TWM2OD1yLkC4NFg3KM7:TR?= NEjsN4RUSU6JRWK=
NCI-H2141 NGrqOFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrnW4FKSzVyPUCuNFgyKM7:TR?= M3\5TnNCVkeHUh?=
LB2518-MEL MoPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoqyTWM2OD1yLkC4NVQyKM7:TR?= NXvidWdTW0GQR1XS
GI-ME-N M{XGeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMEi0OVIh|ryP NXLDbWJKW0GQR1XS
TGW NEXIS4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGX5WXBKSzVyPUCuNFg3ODdizszN M{W0TnNCVkeHUh?=
SK-NEP-1 NYX1RYw{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzTZ5dHUUN3ME2wMlA5PjRzIN88US=> NFfCclFUSU6JRWK=
NOMO-1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fYO2lEPTB;MD6wPVI4PSEQvF2= MXLTRW5ITVJ?
ES6 MknwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPTWWVKSzVyPUCuNFk2QDlizszN M1XKbXNCVkeHUh?=
NCI-H209 NXjVUVhHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPpTWM2OD1yLkC5O|g3KM7:TR?= M{HzcHNCVkeHUh?=
GAK M2nYTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\YUGlEPTB;MD6xNFE3KM7:TR?= MYHTRW5ITVJ?
BC-1 NHewRpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPJTWM2OD1yLkGwN|YyKM7:TR?= MWjTRW5ITVJ?
KLE NYHKWIhRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWfJR|UxRTBwMUC0OFMh|ryP NWT6b|FFW0GQR1XS
EW-3 M1LN[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3Xh[2lEPTB;MD6xNFk5KM7:TR?= MV3TRW5ITVJ?
NKM-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHzFc2pKSzVyPUCuNVEyKM7:TR?= NUTJSVFOW0GQR1XS
D-336MG NUHXUI5JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PVXWlEPTB;MD6xNVI1PCEQvF2= MX7TRW5ITVJ?
NB69 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rnbGlEPTB;MD6xNVMxOSEQvF2= MmXlV2FPT0WU
D-263MG M3fNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlH1TWM2OD1yLkGxO|EzKM7:TR?= NHPERnJUSU6JRWK=
KP-N-YS NVfXZXZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfxTWM2OD1yLkGyNlkyKM7:TR?= MWXTRW5ITVJ?
NCI-H1155 NXzTV21[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRTBwMUK1OVgh|ryP NHLi[5pUSU6JRWK=
BOKU NXPJ[WFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTBwMUK1O|kh|ryP Mkm3V2FPT0WU
LAMA-84 M{Tabmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWn2PYxQUUN3ME2wMlEzQTlizszN NWC4SYFWW0GQR1XS
Raji NVjtXIVOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDMXXVXUUN3ME2wMlE{OTF5IN88US=> M1n1cHNCVkeHUh?=
LU-65 NVi1PYI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTBwMUOzNFch|ryP NVLtOJRFW0GQR1XS
NCI-H187 M3O2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjPUFFpUUN3ME2wMlE{QTJ2IN88US=> MWjTRW5ITVJ?
GCIY NV7oe4lJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S1SGlEPTB;MD6xOFkxOSEQvF2= M2TOTXNCVkeHUh?=
NCI-H2107 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1XGUmlEPTB;MD6xOVA5KM7:TR?= NHTJNnhUSU6JRWK=
NCI-H1522 MkfmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLicYpKSzVyPUCuNVUzPjZizszN NHmxRYFUSU6JRWK=
NB6 NGXLUIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvPRY1lUUN3ME2wMlE2PjJ|IN88US=> NHLxR2dUSU6JRWK=
EM-2 NV;zfYxFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfGSWxFUUN3ME2wMlE2PzB4IN88US=> MlvEV2FPT0WU
HCC2218 NFTwSVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXIUmxLUUN3ME2wMlE2QThizszN NX;rc2xyW0GQR1XS
NCI-H748 NVO3O4dkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXHTWM2OD1yLkG2N|c3KM7:TR?= M1zsSHNCVkeHUh?=
MS-1 M{\NWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwMU[1N|ch|ryP M1O0ZnNCVkeHUh?=
NB5 MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTBwMU[1PVch|ryP NV61Z404W0GQR1XS
OMC-1 NWq3Wo9CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPkTWM2OD1yLkG2Olg5KM7:TR?= MWjTRW5ITVJ?
NCI-H345 M1\Ie2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXT4Oox6UUN3ME2wMlE3QTJ6IN88US=> MnzQV2FPT0WU
L-428 NYP1UFYyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTBwMU[5OFUh|ryP NHfvSXBUSU6JRWK=
SCH MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LLTWlEPTB;MD6xPFY5PSEQvF2= MVHTRW5ITVJ?
NCI-H1417 M3L5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fCc2lEPTB;MD6xPVIzPyEQvF2= MnLkV2FPT0WU
COLO-320-HSR NIXocZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\ybG1GUUN3ME2wMlE6PTN{IN88US=> MmXXV2FPT0WU
BT-474 NIXZXFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHz3bFNKSzVyPUCuNlA5QTJizszN NITPXIZUSU6JRWK=
GDM-1 M3Twb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH1eIVkUUN3ME2wMlIyQTdzIN88US=> Mn7DV2FPT0WU
NCI-H2196 MoPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGS1R2tKSzVyPUCuNlIzOzVizszN MkT4V2FPT0WU
KP-N-RT-BM-1 NVPGWXJUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXrGRXBFUUN3ME2wMlIzOzR7IN88US=> NEjiUYFUSU6JRWK=
KNS-81-FD M2jJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrYTI4xUUN3ME2wMlIzQTV6IN88US=> MWLTRW5ITVJ?
COLO-668 NUnpW3RkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEPtN|hKSzVyPUCuNlM3PzVizszN NYPlUJh1W0GQR1XS
C2BBe1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTtTWM2OD1yLkK2O|Q4KM7:TR?= NYK3SllLW0GQR1XS
Ramos-2G6-4C10 MnHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTBZ2hKSzVyPUCuNlY6PTRizszN M3PNenNCVkeHUh?=
CAS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3RfWlKSzVyPUCuNlcxQTZizszN MWrTRW5ITVJ?
GOTO M3zsVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFnoToZKSzVyPUCuNlc5QTRizszN Mnj0V2FPT0WU
LP-1 NY[wfnR{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{i4PWlEPTB;MD6yPFA2PyEQvF2= MXnTRW5ITVJ?
NCI-SNU-1 NITweoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTBwMkm0NlIh|ryP NWGxV3B[W0GQR1XS
EB-3 MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTBwMkm5O|kh|ryP M3vUSnNCVkeHUh?=
MHH-NB-11 NWfSTFdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTBwM{C0NFIh|ryP NX;pRVA2W0GQR1XS
SK-N-FI M4P5VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPa[FdHUUN3ME2wMlMyPjl{IN88US=> MojsV2FPT0WU
HCC2157 NXLCfHBpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwM{O5NVMh|ryP MUTTRW5ITVJ?
SIMA M{HXbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWD0[VBQUUN3ME2wMlM1PThzIN88US=> Mmm5V2FPT0WU
MDA-MB-134-VI MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXHTWM2OD1yLkO2PVI5KM7:TR?= M3nTXnNCVkeHUh?=
NCI-H1694 M3myVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXJdFlKSzVyPUCuN|ch|ryP M4K2fnNCVkeHUh?=
EHEB MnnuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PYe2lEPTB;MD6zPVA5PSEQvF2= NEXnR2tUSU6JRWK=
U-266 NUDCUpFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PwT2lEPTB;MD6zPVg1PiEQvF2= NYqzOXl7W0GQR1XS
LC-1F MmTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\2R2lEPTB;MD60N|c3PSEQvF2= M1nvNXNCVkeHUh?=
SHP-77 MkL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7DdVd6UUN3ME2wMlQ4QDV3IN88US=> NV3zPIxGW0GQR1XS
LS-513 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVH1b5ZQUUN3ME2wMlQ6OzB5IN88US=> NUDaUWVCW0GQR1XS

... Click to View More Cell Line Experimental Data

体内研究 Paclitaxel单独处理 BC-V 和 BC-ER肿瘤的抑制定额分别为49.78 和 51.23%。20 mg/kg Paclitaxel处理6个周期,显著降低Ki-67阳性细胞百分比,BC-V肿瘤中降到20.4%,BC-ER 肿瘤中降到25.1%。[5]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

细胞实验:

[1]

+ 展开
  • Cell lines: 细胞,包括人类新生儿皮肤微血管内皮细胞(HMVECs), 人脐静脉内皮细胞(HUVECs), 人脐动脉内皮细胞 (HUAVECs), 正常人类星形胶质细胞(NHAs), 正常人体皮肤成纤维细胞(NHDFs), 正常人表皮角质形成细胞(NHEKs), 人类乳腺上皮细胞(HMEpCs), 人前列腺上皮细胞(PrEpCs) 和人脐动脉平滑肌细胞(UASMCs)
  • Concentrations: 0.1 pM-100 pM
  • Incubation Time: 72 小时
  • Method:

    培养细胞,包括人类新生儿皮肤微血管内皮细胞(HMVECs), 人脐静脉内皮细胞(HUVECs), 人脐动脉内皮细胞 (HUAVECs), 正常人类星形胶质细胞(NHAs), 正常人体皮肤成纤维细胞(NHDFs), 正常人表皮角质形成细胞(NHEKs), 人类乳腺上皮细胞(HMEpCs), 人前列腺上皮细胞(PrEpCs) 和人脐动脉平滑肌细胞(UASMCs)。在96孔板中使用6和12通道的细胞进行增殖。细胞按每孔3000–5000个细胞接种,然后粘附4小时。Paclitaxel在培养基中稀释,然后按一式四份加到孔中,细胞温育3天,然后加入MTS 试剂,然后定量测量每孔中的活细胞。


    (Only for Reference)
动物实验:

[5]

+ 展开
  • Animal Models: 携带BC-V 和 BC-ER肿瘤的雌性20-22 g 纯和裸鼠
  • Formulation: Dissolved in absolute ethanol with an equal volume of cremophor and diluted 1:4 with sterile physiological saline before use.
  • Dosages: 20 mg/kg
  • Administration: 静脉注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 171 mg/mL (200.25 mM)
Ethanol 18 mg/mL (21.07 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+5% Tween 80+ddH2O
2.5mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 853.91
化学式

C47H51NO14

CAS号 33069-62-4
稳定性 powder
in solvent
别名 NSC 125973

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03400306 Not yet recruiting Cancer - Ovarian AbbVie May 10 2020 Phase 1
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03417921 Not yet recruiting Pancreatic Cancer Ability Pharmaceuticals SL|The Cleveland Clinic December 1 2019 Phase 1|Phase 2
NCT03818997 Not yet recruiting Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics Inc. August 2019 Phase 2
NCT03818997 Not yet recruiting Esophageal Cancer|Biliary Tract Cancer|GastroEsophageal Cancer|Hepatobiliary Neoplasm European Organisation for Research and Treatment of Cancer - EORTC|Hoffmann-La Roche|Leap Therapeutics Inc. August 2019 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    I am interested in the product S1150 for in vivo studies, could you please give some suggestions for the formulation?

  • 回答:

    S1150 in 1% DMSO+30% polyethylene glycol+1% Tween 80 at 30mg/ml is a suspension. If the you want to inject it, there is another vehicle, 5% DMSO+5% Tween 80+ddH2O. S1150 can dissolve in it at 2.5mg/ml as a clear solution. It is a common formulation we used, but is not cited from reference.

  • 问题 2:

    the compound was dissolved into 1ml DMSO and diluted with 1x PBS or water (500ul + 9.5 ml PBS or water). I found the white precipitation goes out. How to figure it out?

  • 回答:

    Paclitaxel has very low solubility in water based solution and that's why it precipitated out once you dilute the stock with water. The vehicle we suggest is: 1% DMSO+30% polyethylene glycol+1% Tween 80.

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品

Tags: 购买Paclitaxel | Paclitaxel供应商 | 采购Paclitaxel | Paclitaxel价格 | Paclitaxel生产 | 订购Paclitaxel | Paclitaxel代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID